Systems Pharmacology – When multi-targeting is advantageous (Part 2 of 2)

Systems Pharmacology – When multi-targeting is advantageous (Part 2 of 2)

Publication date: Aug 13, 2019

The safety and efficacy of therapeutic drugs still requires improvement. However, the advent of both systems biology and precision medicine has stimulated a rethink on the process of therapeutic drug design and polypharmacology. More recently, the definition of polypharmacology has morphed to represent therapeutic drugs that have been designed deliberately for multi-targeting that affords beneficial effects to the patient. This emerging effort has been labelled ‘Systems Pharmacology’ and the products are referred to as multi-target or systems pharmacology drugs. This episode is part 2 of 2 episodes and goes into more detail on systems pharmacology, going through definitions, combination therapy vs systems pharmacology drugs, implementation and approaches. Original article by Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor If you’d like to view the original article then follow the link below: https://www.ddw-online.com/therapeutics/p322783-perspective-on-systems-pharmacology:-when-multi-targeting-is-advantageous.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/135186/(4)-perspective-on-systems.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

Concepts Keywords
Acute Toxicity Large target networks
Adjunct Professor Virtual pharmaceutical
Affinity Preliminary screening tool
Antimicrobial Biological systems
Applique Drug systems
Aspirin Efficacious drug systems
Biological Activity Advantageous systems
Biotech Social media
Bleeding Obvious applications
CAF Affected biological networks
Cancer Cardiac disease systems
Cardiovascular Disease Pharmaceutical communities
Cath Population systems
Chemotherapy Chemical
Combination Drug Proof systems
Combination Therapy Co morbidity disorders
Complex System Key disease
Coupling CNS disease
Deregulation Complex disease
Dhe Health disease
Diabetes Metabolism disorders
DLP Gastritis
Drug Design Drug disease
Drug Development Cancers
Drug Resistance Such a stroke
Drug Target Diabetes
Dustin Martin Cardiovascular disease
Enzyme Traumatic brain injury
Epilepsy Pain
Excretion Target disease
Farming Diseases
FDA Cardiac disease
Fever Sickle cell disease
FINA Epilepsy
Force Neurological diseases
Formidable Anti inflammatory peptides
Gastritis Chemo
HDL Chemotherapy
Immortality Drug therapies
Incidence Health sciences
Ing Pharmaceutical sciences
Interact Pharmacology
Janitor Drug discovery
Kindness Drug design
Lead Optimization Polypharmacology
Ligand Medication
Lip Systems pharmacology
Lock Drug interaction
Macron Mechanism of action
Mako Combination therapy
Master Key Pdf
Metabolism Drug Discovery
Modulation Pharmacogenetics
Molecular Docking Chemotherapy
Molecule Drug design
Morbidity
Muscular Skeletal
Neurological Diseases
Oxygen
Pain
Pali
Paradigm
Peak
Perturbations
Pharma
Pharmaceutical
Pharmaceutical Company
Pharmacogenetics
Pharmacologic
Pharmacological
Pharmacology
Plastic
Podcast
Precision Medicine
Probability
Promiscuity
Ramsey
Resilience
Salient
Serendipity
Single Point Mutations
Skeleton
Statin
Stroke
Structural Domain
Substrate
Synergistic
Systems Biology
Targeted Therapies
Targeted Therapy
Teal
Throughput
Torture
Toxicity
USP
Winona
Wisconsin

Semantics

Type Source Name
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *